ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Recurrence
Cancer
Hematologic Cancer
Non-Hodgkin Lymphoma
Lymphoma
Leukemia

Multiple Myeloma trials near Birmingham, AL, USA:

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: mRNA-2808

Phase 1, Phase 2

Moderna
Moderna

Birmingham, Alabama, United States and 9 other locations

is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple...

Enrolling
Relapsed/Refractory Multiple Myeloma
Biological: AZD0120

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Birmingham, Alabama, United States and 35 other locations

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (ND...

Enrolling
Multiple Myeloma, Newly Diagnosed
Multiple Myeloma (MM)
Drug: Elranatamab
Drug: Lenalidomide

Phase 2

SCRI Development Innovations

Birmingham, Alabama, United States and 10 other locations

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Carfilzomib

Phase 2

AbbVie
AbbVie

Birmingham, Alabama, United States and 31 other locations

of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longe...

Enrolling
Relapsed/Refractory Multiple Myeloma
Biological: CB-011

Phase 1

Caribou Biosciences

Birmingham, Alabama, United States and 15 other locations

This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma...

Enrolling
Multiple Myeloma
Drug: BMS-986453

Phase 1

Susan Bal

Birmingham, Alabama, United States

of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Biological: Arlocabtagene Autoleucel

Phase 2

Juno Therapeutics

Birmingham, Alabama, United States and 51 other locations

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....

Enrolling
Relapsed and/or Refractory Multiple Myeloma
Drug: Cyclophosphamide
Drug: Fludarabine

Phase 1

Juno Therapeutics

Birmingham, Alabama, United States and 18 other locations

(BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Alnuctamab
Drug: Iberdomide

Phase 1

Juno Therapeutics

Birmingham, Alabama, United States and 18 other locations

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spon...

Enrolling
Multiple Myeloma
Drug: Carfilzomib
Drug: Etentamig

Phase 3

AbbVie
AbbVie

Birmingham, Alabama, United States and 165 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems